{"id":56410,"date":"2023-05-08T17:51:25","date_gmt":"2023-05-08T12:21:25","guid":{"rendered":"https:\/\/corpbiz.io\/learning\/?p=56410"},"modified":"2024-05-02T14:03:05","modified_gmt":"2024-05-02T08:33:05","slug":"price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority","status":"publish","type":"post","link":"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/","title":{"rendered":"Price Regulation of Medical Devices in India under National Pharmaceutical Pricing Authority"},"content":{"rendered":"\n<p>By creating an innovative and globally\ncompetitive industry in India, supported by best-in-class infrastructure, an\nenabling ecosystem, a streamlined regulatory framework, and qualified\nworkforce, the medical devices sector will be put on an accelerated growth path\nto increase access and affordability of products and services of excellent\nquality to meet the evolving needs of patients. With increased access to\npatent-centric, cutting-edge, and reasonably priced healthcare items, India\nwill be able to take the lead globally in the production of medical device\nproducts. The Drugs (Price Control) Order, 2013 (Paragraphs 6 and 19, Drugs\n(Price Control) Order, 2013) gives the Pricing Authority the Authority to\nregulate drug and medical device pricing. Using the trade margin\nrationalization technique (TMR approach), the Pricing Authority has, in this\ncase, set a maximum retail price for the five medical items that were\npreviously mentioned. In this article, we will discuss more about National Pharmaceutical Pricing Authority (NPPA).<\/p>\n\n\n\n<p>With increased access to patent-centric, cutting-edge, and reasonably priced healthcare items, India will be able to take the lead globally in the production of <strong><a href=\"https:\/\/corpbiz.io\/medical-device-registration\">medical device<\/a><\/strong> products. The medications have given the Pricing Authority to regulate the cost of pharmaceuticals and medical devices. The <strong>Niti Aayog<\/strong><sup><a href=\"https:\/\/en.wikipedia.org\/wiki\/NITI_Aayog\"><strong>[1]<\/strong><\/a><\/sup> released a consultation paper in 2017 titled &#8220;Rationalisation of trade margins in medical devices&#8221; as a result of discussions between the healthcare sector and the government in India about using trade margin data to rationalize the cost of medical devices and drugs.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title ez-toc-toggle\" style=\"cursor:pointer\">Page Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/#About_National_Pharmaceutical_Pricing_Authority_NPPA\" >About National Pharmaceutical Pricing Authority (NPPA)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/#What_are_the_Functions_of_National_Pharmaceutical_Pricing_Authority_NPPA\" >What are the Functions of National\nPharmaceutical Pricing Authority (NPPA)?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/#Significance_of_the_National_Pharmaceutical_Pricing_Authority_in_India\" >Significance of the National Pharmaceutical Pricing Authority in India<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/#What_Are_The_Powers_Given_To_The_Authority\" >What Are The Powers Given To The Authority?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/#Initiatives_taken_by_the_National_Pharmaceutical_Pricing_Authority\" >Initiatives taken by the National Pharmaceutical Pricing Authority<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/#Recent_Developments_and_Expanding_Scope\" >Recent Developments and Expanding Scope<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/corpbiz.io\/learning\/price-regulation-of-medical-devices-in-india-under-national-pharmaceutical-pricing-authority\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"About_National_Pharmaceutical_Pricing_Authority_NPPA\"><\/span>About National Pharmaceutical Pricing Authority (NPPA)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On August 29, 1997, the Government of India\n(GOI) passed a resolution which established National Pharmaceutical Pricing\nAuthority. It serves as an independent panel of experts for regulating the price\nof necessary and life-saving drugs and medical devices. The Authority has\nimplemented the Department of Pharmaceuticals (DoP) and the Drugs (Prices\nControl) Orders of 2012. All medical devices listed in Schedule-I of the DPCO,\n2013, are given a ceiling price by NPPA, which also keeps track of annual price\nincreases for both scheduled and unscheduled drugs. It has so far set a cap\nprice for 950 new drugs and 856 planned formulations. In the public interest,\nit has restricted the pricing of 106 anti-diabetic and cardiovascular drugs,\nstents, and knee implants by using the authority granted by Paragraph 19 of the\nDPCO of 2013.<\/p>\n\n\n\n<p>Since its founding, it is expected to have\nhelped consumers save close to INR 11,500 crore. Indian Pharma is currently in\na unique position as the global pharmacy. Among poor nations, it is the top\nsupplier of generic drugs, vaccines, and anti-retrovirals. The $33 billion\npharmaceutical business is booming, and it has a substantial export market.\nTherefore, it is crucial to support Indian pharma while simultaneously ensuring\nfair competition for international businesses under the \u2018Make in India\u2019\ninitiative. In India, however, out-of-pocket medical costs continue to be the\nleading factor in families falling below the poverty line. Under allow its\ncontrol, the Indian government included drugs under section 3 of the Essential\nCommodities Act of 1955. As it affects both the economic sustainability of\ndisadvantaged groups of society and the quality of public health, the\ngovernment is dedicated to enhancing access to necessary and life-saving\nmedications. According to the DPCOs, NPPA aims to achieve a balance between the\nconsumers&#8217; interests and the pharmaceutical industry.<\/p>\n\n\n\n<p>Through the Price Monitoring and Research\nUnits (PMRUs) at State levels, the NPPA extended outside of Delhi for the first\ntime in order to increase monitoring and public awareness. The office of the\nDCGI or Drug Controller General of India, State Drug Controllers, and NIPERs\nare actively working together to collect data, regulate the industry, and\nenhance services to the public. In order to make a legitimate contribution to\npolicy formation at the Department of Pharmaceuticals and NITI Aayog, NPPA also\nattempts to do parallel research and studies.<\/p>\n\n\n\n<p>As a regulator, the National Pharmaceutical\nPricing Authority&#8217;s job is to foster the growth of the Indian pharmaceutical\nindustry into a global leader while simultaneously promoting national health\nthrough the availability and affordability of pharmaceuticals and medical\nequipment. <\/p>\n\n\n\n<p>Here is a diagram outlining each National Pharmaceutical Pricing Authority component for your convenience:<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter\"><img decoding=\"async\" width=\"626\" height=\"249\" src=\"https:\/\/corpbiz.io\/learning\/wp-content\/uploads\/2023\/05\/afdafasfa.png\" alt=\"National Pharmaceutical Pricing \" class=\"wp-image-56412\" srcset=\"https:\/\/corpbiz.io\/learning\/wp-content\/uploads\/2023\/05\/afdafasfa.png 626w, https:\/\/corpbiz.io\/learning\/wp-content\/uploads\/2023\/05\/afdafasfa-300x119.png 300w\" sizes=\"(max-width: 626px) 100vw, 626px\" \/><\/figure><\/div>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_are_the_Functions_of_National_Pharmaceutical_Pricing_Authority_NPPA\"><\/span>What are the Functions of National\nPharmaceutical Pricing Authority (NPPA)?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The\nfollowing are the functions and duties carried out by India&#8217;s National\nPharmaceutical Pricing Authority:<\/p>\n\n\n\n<ul>\n<li>To put into effect and uphold the Drugs Price Control Order&#8217;s (DPCO)\n1995\/2013 provisions in line with the Authority granted to it.<\/li>\n\n\n\n<li>To carry out and\/or support pertinent research about the cost of\nmedications\/formulations.<\/li>\n\n\n\n<li>To keep an eye on medicine supply, spot any shortages, and take action\nif necessary<\/li>\n\n\n\n<li>To gather and retain information on bulk pharmaceuticals and\nformulations on production, exports and imports, individual company market\nshares, company profitability, etc.<\/li>\n\n\n\n<li>To handle any legal issues resulting from the Authority&#8217;s judgements.<\/li>\n\n\n\n<li>To provide the Central Government with advice on alterations or updates\nto the drug policy<\/li>\n\n\n\n<li>To support the Central Government on legislative issues involving drug\nprices.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Significance_of_the_National_Pharmaceutical_Pricing_Authority_in_India\"><\/span>Significance of the National Pharmaceutical Pricing Authority in India<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Under\nthis section the author has explained the importance of\nNational Pharmaceutical Pricing Authority for the country with all the major\nstep it has taken to uplift the pharmaceutical industry during the Covid times.\n<\/p>\n\n\n\n<ul>\n<li>The National Pharmaceutical\nPricing Authority (NPPA) makes sure that the costs of some essential medicines\nand medical equipment are fixed so that every person in the nation may easily\nafford and access them. According to the law, no supplier is allowed to sell a\nmedication or medical equipment for more than its Maximum Retail Price\n(MRP).&nbsp; <\/li>\n\n\n\n<li>National Pharmaceutical Pricing\nAuthority was extremely important during the country&#8217;s pandemic period since\nmany medical providers were selling pharmaceuticals at excessive costs that\nwere out of reach for many people. The Authority set the pricing; as a result,\nmaking them easily accessible to all the citizens.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Are_The_Powers_Given_To_The_Authority\"><\/span>What Are The Powers Given To The Authority?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>You can better grasp the extensive\nauthority granted to the National Pharmaceutical Pricing Authority by looking\nat the following table:<\/p>\n\n\n\n<figure class=\"wp-block-table table table-bordered\"><table><tbody><tr><td>\n  <strong>S. No.<\/strong>\n  <\/td><td>\n  <strong>Power of the authority<\/strong>\n  <\/td><td>\n  <strong>Description of the power<\/strong>\n  <\/td><\/tr><tr><td>\n  1\n  <\/td><td>   <strong>Calculation of process <\/strong>   <\/td><td>\n  Calculating the prices of:\n  Drug\n  formulations&nbsp;(i.e., a medicine processed or containing one or more\n  drugs);Active\n  pharmaceutical ingredients (i.e., any pharmaceutical, chemical,\n  biological\/plant product used in a formulation).<strong><\/strong>\n  \n  <\/td><\/tr><tr><td>\n  2\n  <\/td><td>   <strong>Control of prices<\/strong>    <\/td><td>\n  The Pricing Authority (PA) can put a cap on the\n  prices of drug formulations in instance of the absence of price reduction due\n  to the absence of competition.<strong><\/strong>\n  <\/td><\/tr><tr><td>\n  3\n  <\/td><td>\n  <strong>Notify DFs\n  and APIs<\/strong><strong><\/strong>\n  <\/td><td>\n  Notify active pharmaceutical ingredients &amp; drug\n  formulations \u2013 even if they don&#8217;t feature in the Essential Medicines List in\n  the public interest<strong><\/strong>\n  <\/td><\/tr><tr><td>\n  4\n  <\/td><td>\n  <strong>Price\n  Monitoring<\/strong><strong><\/strong>\n  <\/td><td>\n  The Pricing\n  Authority has a duty to keep a check on the Maximum Retail Price short form\n  MRP of all active pharmaceutical ingredients &amp; drug formulations,\n  whether\/not they are listed in the Essential Medicines List. This is where\n  the Pricing Authority derives its powers of oversight of medical devices.\n  The Pricing\n  Authority make sure that manufacturers &amp; importers do not increase the\n  MRP more than 10 per cent of the MRP of the previous year, through its price\n  monitoring functions. Where an increase is made beyond 10 per cent, the\n  Pricing Authority has the power to reduce it for the following year.\n  &nbsp;The Pricing Authority can recover\n  overcharged amounts\n  <\/td><\/tr><tr><td>\n  5\n  <\/td><td>\n  <strong>Monitoring\n  availability of Listed drug formulations<\/strong><strong><\/strong>\n  <\/td><td>\n  The Pricing Authority has the duty to keep an eye on\n  the availability of these scheduled drug formulations and active\n  pharmaceutical ingredients. \n  Manufacturers and importers these drugs are required\n  to report the following information quarterly:\n  Details of the manufacturer\n  or importer, this include &#8211; name and address of the company;Details of the marketing\n  company (if any), this include &#8211; name and address of the company;Records related to the\n  production or import for each quarter of the year\n  \n  \n  <\/td><\/tr><tr><td>\n  6\n  <\/td><td>\n  <strong>Call for\n  records and conduct inspections<\/strong><strong><\/strong>\n  <\/td><td>\n  It is the duty of all the manufacturers and\n  importers to maintain records related to the sale of active pharmaceutical\n  ingredients &amp; drug formulations and the Pricing Authority has all the\n  right to request these records.<strong><\/strong>\n  <\/td><\/tr><tr><td>\n  7\n  <\/td><td>\n  <strong>Segments\n  exempt from Pricing Authority oversight<\/strong><strong><\/strong>\n  <\/td><td>\n  In the year 2019, the Department of Pharmaceuticals\n  amended the Drug Price Control Order of 2013 to exclude the following types\n  of drugs from price control and&nbsp;\n  monitoring system:\n  \n   Drugs for the treatment of orphan diseases, for example: diseases\n       affecting less than five-lakh people in India);&nbsp;&nbsp;\n   The order has also given five-year exemption from price control\n       and monitoring system to manufacturers of a &#8216;new drug&#8217; patented under\n       Indian patent law. New drug is defined a drug that has not been used in\n       India, or is being proposed for use with new dosages &amp; indications;\n       or a vaccine, gene therapy\/novel delivery system for the drug. \n  \n  <\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Initiatives_taken_by_the_National_Pharmaceutical_Pricing_Authority\"><\/span>Initiatives taken by the National Pharmaceutical Pricing Authority<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The National Pharmaceutical Pricing\nAuthority is also known as NPPA. This Authority has its headquarters in New\nDelhi and has established Price Monitoring and Resource Units (PMRU) in all\nIndian States and Union Territories to expand its reach across the nation. The\nAuthority&#8217;s most significant initiative was CAPPM (full form consumer\nAwareness, publicity and Price monitoring); it helped establish the PMRUs\nnationwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Developments_and_Expanding_Scope\"><\/span>Recent Developments and Expanding Scope<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The Health Ministry broadened the\ndefinition of a medical device in February 2020 to include software designed to\ndiagnose, prevent, treat, monitor, or alleviate any illness, ailment, handicap,\nor damage. With this expanded definition, more gadgets will eventually be\ncontrolled. Additionally, it implies that the Pricing Authority will have more\ndevices available to manage and monitor prices as more gadgets become\n&#8220;notified&#8221;.<\/p>\n\n\n\n<p>In a meeting conducted in late January 200,\nthe Pricing Authority accepted the potential of this heightened control. The\nPricing Authority agreed to study the pricing details of the new gadgets that\nthe Health Ministry had informed them about during this meeting. The sectors\nthat produce or import four recently notified medical devices\u2014nebulizers, blood\npressure monitors, digital thermometers, and glucometers\u2014are presently\nsubmitting information to the Pricing Authority.<\/p>\n\n\n\n<p>This extra layer of compliance might hinder\nIndia&#8217;s Atmanirbhar Bharat initiative in the healthcare sector by disincentivizing\nan industry already burdened by compliance. Recently, the Commerce Minister\nemphasized how India has the lowest manufacturing costs for pharmaceutical\ngoods worldwide, saying that, in an ideal world, innovation could cut\npharmaceutical product costs. It is necessary to assess and harmonize all rules\nand regulations impacting the medical devices industry&#8217;s capacity to deliver\ninexpensive healthcare if the goal is to enhance access to affordable\nhealthcare. Carve-outs have been made, even if only temporarily, for additional\nmedicinal goods, as stated in the table. Some registered medical devices that\nwere produced under programmes like the Production Linked Incentive Scheme may\nbe eligible for time-limited carve-outs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The most vital and fundamental component of\nhealth is medicine. To treat an illness, any system of medicine needs\nmedications that meet the necessary standards. The daily lives of individuals\nnow inevitably include taking medications. The scope and significance of\nmedicine have significantly expanded with the emergence of new illnesses,\nparticularly those like the present Covid &#8211; 19 epidemic. Access to healthcare\nservices also involves the affordability of high-quality medical equipment.<\/p>\n\n\n\n<p>The pharmaceutical industry is essential to India&#8217;s economic growth and population health. The pharmaceutical industry is responsible for drug invention, development, manufacture, and marketing. The government is responsible for ensuring the availability of life-saving medications at fair pricing by taking into account the interests of both the manufacturers and the consumers. The National Pharmaceutical Pricing Authority (NPPA) is the watchdog in India that regulates medicine pricing in order to protect public health. This article&#8217;s primary goal is to identify the various roles that the NPPA has played in regulating medicine pricing in India.<\/p>\n\n\n\n<p class=\"text-left\"><b>Read Our Article<\/b>: <mark style=\"background: #fffd03 !important;\"><a href=\"https:\/\/corpbiz.io\/learning\/importance-of-medical-device-compliance-in-india\/\">Importance Of Medical Device Compliance In India \u2013 An Overview<\/a><\/mark><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By creating an innovative and globally competitive industry in India, supported by best-in-class infrastructure, an enabling ecosystem, a streamlined regulatory framework, and qualified workforce, the medical devices sector will be put on an accelerated growth path to increase access and affordability of products and services of excellent quality to meet the evolving needs of patients. [&hellip;]<\/p>\n","protected":false},"author":48,"featured_media":56413,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[946],"tags":[3587],"acf":{"service_id":"385"},"authorName":"Astitva Kumar","authorImageUrl":"https:\/\/corpbiz.io\/learning\/wp-content\/uploads\/2022\/12\/MicrosoftTeams-image-27.jpg","authorDescription":"Astitva Kumar is an advocate by profession and has completed her BBA. LLB from IP University. She is an avid reader, researcher, and legal writer. Her areas of interest include mediation, conflict resolution, finance, cyber laws, and taxation.","postViews":4409,"readingTime":7,"_links":{"self":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/56410"}],"collection":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/users\/48"}],"replies":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/comments?post=56410"}],"version-history":[{"count":7,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/56410\/revisions"}],"predecessor-version":[{"id":63913,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/posts\/56410\/revisions\/63913"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media\/56413"}],"wp:attachment":[{"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/media?parent=56410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/categories?post=56410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/corpbiz.io\/learning\/wp-json\/wp\/v2\/tags?post=56410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}